{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:47:02Z","timestamp":1764175622231,"version":"build-2065373602"},"reference-count":152,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Pleural mesothelioma is a rare neoplastic disease with aggressive features. Patient\nsurvival is poor due to the lack of early symptoms and the absence of effective therapeutic\nstrategies. The development of pleural mesothelioma is mainly associated to\nasbestos exposure and related chronic inflammation. From a molecular-based perspective,\nthis disease is a heterogeneous tumor lacking actionable alterations. The median\noverall survival of patients affected by this tumor does not exceed 16 months from diagnosis.\nMolecular and biochemical approaches have shown that this disease is characterized\nby resistance to drug-induced apoptosis associated with the activation of cell survival\npathways and expression of anti-apoptotic proteins. Thus, there is an urgent need to\ndevelop efficient and safe therapeutic strategies. Here, we review the pharmacological\noptions available for the treatment of this disease with specific reference to the antitumor\nagents used in systemic therapies. In addition, novel pharmacological approaches,\nsuch as drug delivery tools, to improve pleural mesothelioma treatment are discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673268206240405084558","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T09:48:12Z","timestamp":1713347292000},"page":"2093-2114","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma"],"prefix":"10.2174","volume":"32","author":[{"given":"Luca","family":"Mirra","sequence":"first","affiliation":[{"name":"Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Luca","family":"Beretta","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Lisini","sequence":"additional","affiliation":[{"name":"Cell Therapy\nProduction Unit, Scientific Direction, IRCCS Neurological Institute Carlo Besta Foundation, Milan,\n20133, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Marcianti","sequence":"additional","affiliation":[{"name":"Cell Therapy\nProduction Unit, Scientific Direction, IRCCS Neurological Institute Carlo Besta Foundation, Milan,\n20133, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Spampinato","sequence":"additional","affiliation":[{"name":"Cell Therapy\nProduction Unit, Scientific Direction, IRCCS Neurological Institute Carlo Besta Foundation, Milan,\n20133, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Corno","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Costantino","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Corsico","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia,\n27100 , Italy"},{"name":"Unit of Respiratory Diseases, Cardio-Thoraco-Vascular Department, IRCCS Policlinico San\nMatteo Foundation, Pavia, 27100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia Maria","family":"Stella","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia,\n27100 , Italy"},{"name":"Unit of Respiratory Diseases, Cardio-Thoraco-Vascular Department, IRCCS Policlinico San\nMatteo Foundation, Pavia, 27100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Perego","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/cancers12051186","volume":"12","author":"Abbott D.M.","year":"2020","unstructured":"Abbott D.M.; Bortolotto C.; Benvenuti S.; Lancia A.; Filippi A.R.; Stella G.M.; Malignant Pleural Mesothelioma: Genetic and microenviromental heterogeneity as an unexpected reading frame and therapeutic challenge. Cancers  2020,12(5),1186","journal-title":"Cancers"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1183\/09059180.00007014","volume":"24","author":"R\u00f8e O.D.","year":"2015","unstructured":"R\u00f8e O.D.; Stella G.M.; Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev  2015,24(135),115-131","journal-title":"Eur Respir Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"E254","DOI":"10.3978\/j.issn.2072-1439.2013.11.28","volume":"5","author":"van Zandwijk N.","year":"2013","unstructured":"van Zandwijk N.; Clarke C.; Henderson D.; Musk A.W.; Fong K.; Nowak A.; Loneragan R.; McCaughan B.; Boyer M.; Feigen M.; Currow D.; Schofield P.; Nick Pavlakis B.I.; McLean J.; Marshall H.; Leong S.; Keena V.; Penman A.; Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis  2013,5(6),E254-E307","journal-title":"J Thorac Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","volume":"196","author":"Meyerhoff R.R.","year":"2015","unstructured":"Meyerhoff R.R.; Yang C.F.J.; Speicher P.J.; Gulack B.C.; Hartwig M.G.; D\u2019Amico T.A.; Harpole D.H.; Berry M.F.; Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res  2015,196(1),23-32","journal-title":"J Surg Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","volume":"142","author":"Attanoos R.L.","year":"2018","unstructured":"Attanoos R.L.; Churg A.; Galateau-Salle F.; Gibbs A.R.; Roggli V.L.; Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med  2018,142(6),753-760","journal-title":"Arch Pathol Lab Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00280-019-03878-3","volume":"84","author":"Galani V.","year":"2019","unstructured":"Galani V.; Varouktsi A.; Papadatos S.S.; Mitselou A.; Sainis I.; Constantopoulos S.; Dalavanga Y.; The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. Cancer Chemother Pharmacol  2019,84(2),241-253","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","volume":"7","author":"Broeckx G.","year":"2018","unstructured":"Broeckx G.; Pauwels P.; Malignant peritoneal mesothelioma: A review. Transl Lung Cancer Res  2018,7(5),537-542","journal-title":"Transl Lung Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10937404.2016.1193361","volume":"19","author":"Andujar P.","year":"2016","unstructured":"Andujar P.; Lacourt A.; Brochard P.; Pairon J.C.; Jaurand M.C.; Jean D.; Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. J Toxicol Environ Health B Crit Rev  2016,19(5-6),151-172","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","volume":"13","author":"McCambridge A.J.","year":"2018","unstructured":"McCambridge A.J.; Napolitano A.; Mansfield A.S.; Fennell D.A.; Sekido Y.; Nowak A.K.; Reungwetwattana T.; Mao W.; Pass H.I.; Carbone M.; Yang H.; Peikert T.; Progress in the management of malignant pleural mesothelioma in 2017. J Thorac Oncol  2018,13(5),606-623","journal-title":"J Thorac Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"934","DOI":"10.21037\/tlcr-2019-pps-10","volume":"9","author":"Hjerpe A.","year":"2020","unstructured":"Hjerpe A.; Own S.A.; Dobra K.; Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma. Transl Lung Cancer Res  2020,9(3),934-943","journal-title":"Transl Lung Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/bjc.2015.286","volume":"113","author":"Kirschner M.B.","year":"2015","unstructured":"Kirschner M.B.; Pulford E.; Hoda M.A.; Rozsas A.; Griggs K.; Cheng Y.Y.; Edelman J.J.B.; Kao S.C.; Hyland R.; Dong Y.; L\u00e1szl\u00f3 V.; Klikovits T.; Vallely M.P.; Grusch M.; Hegedus B.; Dome B.; Klepetko W.; van Zandwijk N.; Klebe S.; Reid G.; Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer  2015,113(6),963-969","journal-title":"Br J Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/his.13470","volume":"72","author":"Rrapaj E.","year":"2018","unstructured":"Rrapaj E.; Trisolini E.; Bertero L.; Salvo M.; Indellicato R.; Andorno S.; Garcia-Manteiga J.M.; Rena O.; Boldorini R.L.; Expression analysis of  1 in histological samples of malignant pleural mesothelioma. Histopathology  2018,72(6),1039-1050","journal-title":"Histopathology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/8628612","volume":"2019","author":"Birnie K.A.","year":"2019","unstructured":"Birnie K.A.; Pr\u00eale C.M.; Musk A.W.B.; de Klerk N.; Lee Y.C.G.; Fitzgerald D.; Allcock R.J.N.; Thompson P.J.; Creaney J.; Badrian B.; Mutsaers S.E.; MicroRNA signatures in malignant pleural mesothelioma effusions. Dis Markers  2019,2019,1-9","journal-title":"Dis Markers"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"Bueno R.","year":"2016","unstructured":"Bueno R.; Stawiski E.W.; Goldstein L.D.; Durinck S.; De Rienzo A.; Modrusan Z.; Gnad F.; Nguyen T.T.; Jaiswal B.S.; Chirieac L.R.; Sciaranghella D.; Dao N.; Gustafson C.E.; Munir K.J.; Hackney J.A.; Chaudhuri A.; Gupta R.; Guillory J.; Toy K.; Ha C.; Chen Y.J.; Stinson J.; Chaudhuri S.; Zhang N.; Wu T.D.; Sugarbaker D.J.; de Sauvage F.J.; Richards W.G.; Seshagiri S.; Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet  2016,48(4),407-416","journal-title":"Nat Genet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Blum Y.","year":"2019","unstructured":"Blum Y.; Meiller C.; Quetel L.; Elarouci N.; Ayadi M.; Tashtanbaeva D.; Armenoult L.; Montagne F.; Tranchant R.; Renier A.; de Koning L.; Copin M.C.; Hofman P.; Hofman V.; Porte H.; Le Pimpec-Barthes F.; Zucman-Rossi J.; Jaurand M.C.; de Reyni\u00e8s A.; Jean D.; Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun  2019,10(1),1333","journal-title":"Nat Commun"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Sekido Y.","year":"2013","unstructured":"Sekido Y.; Molecular pathogenesis of malignant mesothelioma. Carcinogenesis  2013,34(7),1413-1419","journal-title":"Carcinogenesis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"Scherpereel A.","year":"2018","unstructured":"Scherpereel A.; Wallyn F.; Albelda S.M.; Munck C.; Novel therapies for malignant pleural mesothelioma. Lancet Oncol  2018,19(3),e161-e172","journal-title":"Lancet Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00595-015-1275-3","volume":"46","author":"Takuwa T.","year":"2016","unstructured":"Takuwa T.; Hasegawa S.; Current surgical strategies for malignant pleural mesothelioma. Surg Today  2016,46(8),887-894","journal-title":"Surg Today"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.08.011","volume":"107","author":"Bronte G.","year":"2016","unstructured":"Bronte G.; Incorvaia L.; Rizzo S.; Passiglia F.; Galvano A.; Rizzo F.; Rolfo C.; Fanale D.; List\u00ec A.; Natoli C.; Bazan V.; Russo A.; The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? Crit Rev Oncol Hematol  2016,107,20-32","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","volume":"17","author":"Borczuk A.C.","year":"2016","unstructured":"Borczuk A.C.; Pei J.; Taub R.N.; Levy B.; Nahum O.; Chen J.; Chen K.; Testa J.R.; Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther  2016,17(3),328-335","journal-title":"Cancer Biol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"Guo G.","year":"2015","unstructured":"Guo G.; Chmielecki J.; Goparaju C.; Heguy A.; Dolgalev I.; Carbone M.; Seepo S.; Meyerson M.; Pass H.I.; Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res  2015,75(2),264-269","journal-title":"Cancer Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","volume":"20","author":"de Reyni\u00e8s A.","year":"2014","unstructured":"de Reyni\u00e8s A.; Jaurand M.C.; Renier A.; Couchy G.; Hysi I.; Elarouci N.; Galateau-Sall\u00e9 F.; Copin M.C.; Hofman P.; Cazes A.; Andujar P.; Imbeaud S.; Petel F.; Pairon J.C.; Le Pimpec-Barthes F.; Zucman-Rossi J.; Jean D.; Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res  2014,20(5),1323-1334","journal-title":"Clin Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","volume":"136","author":"Jean D.","year":"2012","unstructured":"Jean D.; Daubriac J.; Le Pimpec-Barthes F.; Galateau-Salle F.; Jaurand M.C.; Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med  2012,136(3),277-293","journal-title":"Arch Pathol Lab Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"Nasu M.","year":"2015","unstructured":"Nasu M.; Emi M.; Pastorino S.; Tanji M.; Powers A.; Luk H.; Baumann F.; Zhang Y.; Gazdar A.; Kanodia S.; Tiirikainen M.; Flores E.; Gaudino G.; Becich M.J.; Pass H.I.; Yang H.; Carbone M.; High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol  2015,10(4),565-576","journal-title":"J Thorac Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbamcr.2013.06.027","volume":"1843","author":"Eletr Z.M.","year":"2014","unstructured":"Eletr Z.M.; Wilkinson K.D.; Regulation of proteolysis by human deubiquitinating enzymes. Biochim Biophys Acta Mol Cell Res  2014,1843(1),114-128","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","volume":"546","author":"Bononi A.","year":"2017","unstructured":"Bononi A.; Giorgi C.; Patergnani S.; Larson D.; Verbruggen K.; Tanji M.; Pellegrini L.; Signorato V.; Olivetto F.; Pastorino S.; Nasu M.; Napolitano A.; Gaudino G.; Morris P.; Sakamoto G.; Ferris L.K.; Danese A.; Raimondi A.; Tacchetti C.; Kuchay S.; Pass H.I.; Affar E.B.; Yang H.; Pinton P.; Carbone M.; BAP1 regulates IP3R3-mediated Ca flux to mitochondria suppressing cell transformation. Nature  2017,546(7659),549-553","journal-title":"Nature"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","volume":"10","author":"Carbone M.","year":"2020","unstructured":"Carbone M.; Harbour J.W.; Brugarolas J.; Bononi A.; Pagano I.; Dey A.; Krausz T.; Pass H.I.; Yang H.; Gaudino G.; Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov  2020,10(8),1103-1120","journal-title":"Cancer Discov"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1074\/mcp.RA119.001457","volume":"18","author":"Chen P.","year":"2019","unstructured":"Chen P.; Wang H.; Zhang W.; Chen Y.; Lv Y.; Wu D.; Guo M.; Deng H.; Loss of BAP1 Results in growth inhibition and enhances mesenchymal\u2013epithelial transition in kidney tumor cells. Mol Cell Proteomics  2019,18(7),1320-1329","journal-title":"Mol Cell Proteomics"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","volume":"9","author":"Affar E.B.","year":"2018","unstructured":"Affar E.B.; Carbone M.; BAP1 regulates different mechanisms of cell death. Cell Death Dis  2018,9(12),1151","journal-title":"Cell Death Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Zhang Y.","year":"2018","unstructured":"Zhang Y.; Shi J.; Liu X.; Feng L.; Gong Z.; Koppula P.; Sirohi K.; Li X.; Wei Y.; Lee H.; Zhuang L.; Chen G.; Xiao Z.D.; Hung M.C.; Chen J.; Huang P.; Li W.; Gan B.; BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol  2018,20(10),1181-1192","journal-title":"Nat Cell Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/biology2010040","volume":"2","author":"Christou C.","year":"2013","unstructured":"Christou C.; Kyriacou K.; BRCA1 and its network of interacting partners. Biology  2013,2(1),40-63","journal-title":"Biology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.7150\/jca.33316","volume":"11","author":"Zhang N.","year":"2020","unstructured":"Zhang N.; Chen S.; Jiang G.; Wu Y.; Shao J.; Liu W.; Wang X.; Na R.; Xu J.; The study on copy number alteration of clear cell renal cancer in Chinese population. J Cancer  2020,11(1),16-24","journal-title":"J Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","volume":"36","author":"Pastorino S.","year":"2018","unstructured":"Pastorino S.; Yoshikawa Y.; Pass H.I.; Emi M.; Nasu M.; Pagano I.; Takinishi Y.; Yamamoto R.; Minaai M.; Hashimoto-Tamaoki T.; Ohmuraya M.; Goto K.; Goparaju C.; Sarin K.Y.; Tanji M.; Bononi A.; Napolitano A.; Gaudino G.; Hesdorffer M.; Yang H.; Carbone M.; A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol  2018,36(35),3485-3494","journal-title":"J Clin Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"Panou V.","year":"2018","unstructured":"Panou V.; Gadiraju M.; Wolin A.; Weipert C.M.; Skarda E.; Husain A.N.; Patel J.D.; Rose B.; Zhang S.R.; Weatherly M.; Nelakuditi V.; Knight Johnson A.; Helgeson M.; Fischer D.; Desai A.; Sulai N.; Ritterhouse L.; R\u00f8e O.D.; Turaga K.K.; Huo D.; Segal J.; Kadri S.; Li Z.; Kindler H.L.; Churpek J.E.; Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol  2018,36(28),2863-2871","journal-title":"J Clin Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","volume":"116","author":"Hassan R.","year":"2019","unstructured":"Hassan R.; Morrow B.; Thomas A.; Walsh T.; Lee M.K.; Gulsuner S.; Gadiraju M.; Panou V.; Gao S.; Mian I.; Khan J.; Raffeld M.; Patel S.; Xi L.; Wei J.S.; Hesdorffer M.; Zhang J.; Calzone K.; Desai A.; Padiernos E.; Alewine C.; Schrump D.S.; Steinberg S.M.; Kindler H.L.; King M.C.; Churpek J.E.; Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci  2019,116(18),9008-9013","journal-title":"Proc Natl Acad Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.3390\/ijms21124327","volume":"21","author":"Panou V.","year":"2020","unstructured":"Panou V.; R\u00f8e O.D.; Inherited genetic mutations and polymorphisms in malignant mesothelioma: A comprehensive review. Int J Mol Sci  2020,21(12),4327","journal-title":"Int J Mol Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/gcc.22424","volume":"56","author":"Rai K.","year":"2017","unstructured":"Rai K.; Pilarski R.; Boru G.; Rehman M.; Saqr A.H.; Massengill J.B.; Singh A.; Marino M.J.; Davidorf F.H.; Cebulla C.M.; Abdel-Rahman H.; Germline M.; BAP1 alterations in familial uveal melanoma: BAP1 in familial uveal melanoma. Genes Chromosomes Cancer  2017,56(2),168-174","journal-title":"Genes Chromosomes Cancer"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","volume":"153","author":"Haugh A.M.","year":"2017","unstructured":"Haugh A.M.; Njauw C.N.; Bubley J.A.; Verz\u00ec A.E.; Zhang B.; Kudalkar E.; VandenBoom T.; Walton K.; Swick B.L.; Kumar R.; Rana H.Q.; Cochrane S.; McCormick S.R.; Shea C.R.; Tsao H.; Gerami P.; Genotypic and phenotypic features of BAP1 cancer syndrome: A report of 8 new families and review of cases in the literature. JAMA Dermatol  2017,153(10),999-1006","journal-title":"JAMA Dermatol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41379-021-00900-z","volume":"35","author":"Roy S.","year":"2022","unstructured":"Roy S.; Galateau-Sall\u00e9 F.; Le Stang N.; Churg A.; Lyons M.A.; Attanoos R.; Dacic S.; Molecular characterization of pleomorphic mesothelioma: a multi-institutional study. Mod Pathol  2022,35(1),82-86","journal-title":"Mod Pathol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.trecan.2016.11.006","volume":"3","author":"Knudsen E.S.","year":"2017","unstructured":"Knudsen E.S.; Witkiewicz A.K.; The Strange case of CDK4\/6 inhibitors: Mechanisms, resistance, and combination strategies. Trends Cancer  2017,3(1),39-55","journal-title":"Trends Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","volume":"6","author":"Cheung M.","year":"2017","unstructured":"Cheung M.; Testa J.R.; BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res  2017,6(3),270-278","journal-title":"Transl Lung Cancer Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","volume":"19","author":"Sato T.","year":"2018","unstructured":"Sato T.; Sekido Y.; NF2\/Merlin Inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci  2018,19(4),988","journal-title":"Int J Mol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","volume":"20","author":"Tang T.T.","year":"2021","unstructured":"Tang T.T.; Konradi A.W.; Feng Y.; Peng X.; Ma M.; Li J.; Yu F.X.; Guan K.L.; Post L.; Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2 -deficient Mesothelioma. Mol Cancer Ther  2021,20(6),986-998","journal-title":"Mol Cancer Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"Shapiro I.M.","year":"2014","unstructured":"Shapiro I.M.; Kolev V.N.; Vidal C.M.; Kadariya Y.; Ring J.E.; Wright Q.; Weaver D.T.; Menges C.; Padval M.; McClatchey A.I.; Xu Q.; Testa J.R.; Pachter J.A.; Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med  2014,6(237),237ra68","journal-title":"Sci Transl Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","volume":"10","author":"Lo Iacono M.","year":"2015","unstructured":"Lo Iacono M.; Monica V.; Righi L.; Grosso F.; Libener R.; Vatrano S.; Bironzo P.; Novello S.; Musmeci L.; Volante M.; Papotti M.; Scagliotti G.V.; Targeted next- generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol  2015,10(3),492-499","journal-title":"J Thorac Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/0008-5472.CAN-15-0751","volume":"76","author":"De Rienzo A.","year":"2016","unstructured":"De Rienzo A.; Archer M.A.; Yeap B.Y.; Dao N.; Sciaranghella D.; Sideris A.C.; Zheng Y.; Holman A.G.; Wang Y.E.; Dal Cin P.S.; Fletcher J.A.; Rubio R.; Croft L.; Quackenbush J.; Sugarbaker P.E.; Munir K.J.; Battilana J.R.; Gustafson C.E.; Chirieac L.R.; Ching S.M.; Wong J.; Tay L.C.; Rudd S.; Hercus R.; Sugarbaker D.J.; Richards W.G.; Bueno R.; Gender-specific molecular and clinical features underlie malignant pleural mesothelioma. Cancer Res  2016,76(2),319-328","journal-title":"Cancer Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.lungcan.2018.03.009","volume":"119","author":"Sneddon S.","year":"2018","unstructured":"Sneddon S.; Dick I.; Lee Y.C.G.; Musk A.W.B.; Patch A.M.; Pearson J.V.; Waddell N.; Allcock R.J.N.; Holt R.A.; Robinson B.W.S.; Creaney J.; Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer  2018,119,64-70","journal-title":"Lung Cancer"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"Hmeljak J.","year":"2018","unstructured":"Hmeljak J.; Sanchez-Vega F.; Hoadley K.A.; Shih J.; Stewart C.; Heiman D.; Tarpey P.; Danilova L.; Drill E.; Gibb E.A.; Bowlby R.; Kanchi R.; Osmanbeyoglu H.U.; Sekido Y.; Takeshita J.; Newton Y.; Graim K.; Gupta M.; Gay C.M.; Diao L.; Gibbs D.L.; Thorsson V.; Iype L.; Kantheti H.; Severson D.T.; Ravegnini G.; Desmeules P.; Jungbluth A.A.; Travis W.D.; Dacic S.; Chirieac L.R.; Galateau-Sall\u00e9 F.; Fujimoto J.; Husain A.N.; Silveira H.C.; Rusch V.W.; Rintoul R.C.; Pass H.; Kindler H.; Zauderer M.G.; Kwiatkowski D.J.; Bueno R.; Tsao A.S.; Creaney J.; Lichtenberg T.; Leraas K.; Bowen J.; Felau I.; Zenklusen J.C.; Akbani R.; Cherniack A.D.; Byers L.A.; Noble M.S.; Fletcher J.A.; Robertson A.G.; Shen R.; Aburatani H.; Robinson B.W.; Campbell P.; Ladanyi M.; Aburatani H.; Akbani R.; Ally A.; Anur P.; Armenia J.; Auman J.T.; Balasundaram M.; Balu S.; Baylin S.B.; Becich M.; Behrens C.; Beroukhim R.; Bielski C.; Bodenheimer T.; Bootwalla M.S.; Bowen J.; Bowlby R.; Brooks D.; Bueno R.; Byers L.A.; C\u00e1rcano F.M.; Carlsen R.; Carvalho A.L.; Cherniack A.D.; Cheung D.; Chirieac L.; Cho J.; Chuah E.; Chudamani S.; Cibulskis C.; Cope L.; Crain D.; Creaney J.; Curley E.; Dacic S.; Danilova L.; Rienzo A.D.; DeFreitas T.; Demchok J.A.; Dhalla N.; Dhir R.; Diao L.; Drill E.; Felau I.; Feldman M.; Ferguson M.L.; Fletcher J.A.; Fujimoto J.; Fujimoto J.; Fukuda S.; Gabriel S.B.; Sall\u00e9 F.G.; Gao J.; Gardner J.; Gastier-Foster J.M.; Gay C.M.; Gehlenborg N.; Gerken M.; Getz G.; Gibb E.A.; Gibbs D.L.; Goparaju C.; Graim K.; Gross B.; Guo G.; Gupta M.; Hasegawa S.; Haussler D.; Hayes D.N.; Heiman D.I.; Heins Z.; Hmeljak J.; Hoadley K.A.; Holt R.A.; Hoyle A.P.; Husain A.; Hutter C.M.; Iype L.; Jefferys S.R.; Jones S.J.M.; Jones C.D.; Kanchi R.S.; Kasaian K.; Kim J.; Kindler H.; Kondo N.; Krausz T.; Kundra R.; Kuribayashi K.; Kwiatkowski D.J.; Ladanyi M.; Lai P.H.; Laird P.W.; Lawrence M.S.; Lee D.; Leraas K.M.; Lichtenberg T.M.; Lin P.; Liu J.; Liu W.; Liu E.M.; Lolla L.; Longatto-Filho A.; Lu Y.; Luketich J.; Ma Y.; Maglinte D.T.; Mallory D.; Marra M.A.; Mayo M.; Meier S.; Melamed J.; Meng S.; Meyerson M.; Mieczkowski P.A.; Mills G.B.; Moore R.A.; Moran C.; Morris S.; Mose L.E.; Mungall A.J.; Mungall K.; Nakano T.; Naresh R.; Newton Y.; Noble M.S.; Ochoa A.; Osmanbeyoglu H.; Parker J.S.; Pass H.I.; Paulauskis J.; Pennathur A.; Pennell N.A.; Penny R.; Perou C.M.; Pihl T.; Ramirez N.C.; Rassl D.M.; Ravegnini G.; Reid G.; Reis R.M.; Reynolds S.M.; Rice D.; Richards W.G.; Rintoul R.C.; Roach J.; Robertson A.G.; Rusch V.; Sadeghi S.; Saksena G.; Sanchez-Vega F.; Sander C.; Sato A.; Scapulatempo-Neto C.; Schein J.E.; Schultz N.; Schumacher S.E.; Seiwert T.; Sekido Y.; Severson D.T.; Shelton C.; Shelton T.; Shen R.; Sheridan R.; Shi Y.; Shih J.; Shiraishi Y.; Shmulevich I.; Silveira H.C.S.; Simons J.V.; Sipahimalani P.; Skelly T.; Sofia H.J.; Soloway M.G.; Spellman P.; Stewart C.; Stuart J.; Sun Q.; Takeshita J.; Tam A.; Tan D.; Tarnuzzer R.; Tatsuno K.; Taylor B.S.; Thiessen N.; Thompson E.; Thorsson V.; Travis W.D.; Tsao A.; Tse K.; Tsujimura T.; Valdivieso F.; Van Den Berg D.J.; van Zandwijk N.; Veluvolu U.; Viana L.S.; Voet D.; Wan Y.; Wang Z.; Wang J.; Weaver J.; Weinstein J.N.; Weisenberger D.J.; Wilkerson M.D.; Wise L.; Wistuba I.; Wong T.; Wu Y.; Yamamoto S.; Yang L.; Zauderer M.G.; Zenklusen J.C.; Zhang J.; Zhang H.; Zhang H.; Zmuda E.; Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov  2018,8(12),1548-1565","journal-title":"Cancer Discov"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","volume":"23","author":"Tranchant R.","year":"2017","unstructured":"Tranchant R.; Quetel L.; Tallet A.; Meiller C.; Renier A.; de Koning L.; de Reynies A.; Le Pimpec-Barthes F.; Zucman-Rossi J.; Jaurand M.C.; Jean D.; Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res  2017,23(12),3191-3202","journal-title":"Clin Cancer Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"113673","DOI":"10.18632\/oncotarget.22817","volume":"8","author":"Hylebos M.","year":"2017","unstructured":"Hylebos M.; Van Camp G.; Vandeweyer G.; Fransen E.; Beyens M.; Cornelissen R.; Suls A.; Pauwels P.; van Meerbeeck J.P.; Op de Beeck K.; Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. Oncotarget  2017,8(69),113673-113686","journal-title":"Oncotarget"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1038\/onc.2013.351","volume":"33","author":"Tallet A.","year":"2014","unstructured":"Tallet A.; Nault J-C.; Renier A.; Hysi I.; Galateau-Sall\u00e9 F.; Cazes A.; Copin M-C.; Hofman P.; Andujar P.; Le Pimpec-Barthes F.; Zucman-Rossi J.; Jaurand M-C.; Jean D.; Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene  2014,33(28),3748-3752","journal-title":"Oncogene"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"Quetel L.","year":"2020","unstructured":"Quetel L.; Meiller C.; Assi\u00e9 J.B.; Blum Y.; Imbeaud S.; Montagne F.; Tranchant R.; de Wolf J.; Caruso S.; Copin M.C.; Hofman V.; Gibault L.; Badoual C.; Pintilie E.; Hofman P.; Monnet I.; Scherpereel A.; Le Pimpec-Barthes F.; Zucman-Rossi J.; Jaurand M.C.; Jean D.; Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol  2020,14(6),1207-1223","journal-title":"Mol Oncol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","volume":"15","author":"Kato S.","year":"2016","unstructured":"Kato S.; Tomson B.N.; Buys T.P.H.; Elkin S.K.; Carter J.L.; Kurzrock R.; Genomic landscape of malignant mesotheliomas. Mol Cancer Ther  2016,15(10),2498-2507","journal-title":"Mol Cancer Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12885-017-3382-6","volume":"17","author":"Sneddon S.","year":"2017","unstructured":"Sneddon S.; Patch A.M.; Dick I.M.; Kazakoff S.; Pearson J.V.; Waddell N.; Allcock R.J.N.; Holt R.A.; Robinson B.W.S.; Creaney J.; Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer  2017,17(1),396","journal-title":"BMC Cancer"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","volume":"110","author":"Zhou S.","year":"2014","unstructured":"Zhou S.; Liu L.; Li H.; Eilers G.; Kuang Y.; Shi S.; Yan Z.; Li X.; Corson J.M.; Meng F.; Zhou H.; Sheng Q.; Fletcher J.A.; Ou W-B.; Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma. Br J Cancer  2014,110(10),2479-2488","journal-title":"Br J Cancer"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s13277-012-0615-9","volume":"34","author":"Agarwal V.","year":"2013","unstructured":"Agarwal V.; Campbell A.; Beaumont K.L.; Cawkwell L.; Lind M.J.; PTEN protein expression in malignant pleural mesothelioma. Tumour Biol  2013,34(2),847-851","journal-title":"Tumour Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/bjc.2013.130","volume":"108","author":"Mezzapelle R.","year":"2013","unstructured":"Mezzapelle R.; Miglio U.; Rena O.; Paganotti A.; Allegrini S.; Antona J.; Molinari F.; Frattini M.; Monga G.; Alabiso O.; Boldorini R.; Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. Br J Cancer  2013,108(8),1743-1749","journal-title":"Br J Cancer"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"Hiltbrunner S.","year":"2022","unstructured":"Hiltbrunner S.; Fleischmann Z.; Sokol E.S.; Zoche M.; Felley-Bosco E.; Curioni-Fontecedro A.; Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer  2022,127(11),1997-2005","journal-title":"Br J Cancer"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2020.00126","volume":"10","author":"Nowak A.K.","year":"2020","unstructured":"Nowak A.K.; Brosseau S.; Cook A.; Zalcman G.; Antiangiogeneic strategies in Mesothelioma. Front Oncol  2020,10,126","journal-title":"Front Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/annonc\/mdu127","volume":"25","author":"Suraokar M.B.","year":"2014","unstructured":"Suraokar M.B.; Nunez M.I.; Diao L.; Chow C.W.; Kim D.; Behrens C.; Lin H.; Lee S.; Raso G.; Moran C.; Rice D.; Mehran R.; Lee J.J.; Pass H.I.; Wang J.; Momin A.A.; James B.P.; Corvalan A.; Coombes K.; Tsao A.; Wistuba I.I.; Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol  2014,25(6),1184-1192","journal-title":"Ann Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/JTO.0b013e3182a59f45","volume":"8","author":"Al\u00ec G.","year":"2013","unstructured":"Al\u00ec G.; Borrelli N.; Riccardo G.; Proietti A.; Pelliccioni S.; Niccoli C.; Boldrini L.; Lucchi M.; Mussi A.; Fontanini G.; Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol  2013,8(11),1389-1395","journal-title":"J Thorac Oncol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.21037\/jtd.2017.10.158","volume":"10","author":"Barone E.","year":"2018","unstructured":"Barone E.; Gemignani F.; Landi S.; Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. J Thorac Dis  2018,10(S2)(Suppl. 2),S369-S382","journal-title":"J Thorac Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/ijms20010150","volume":"20","author":"Turini S.","year":"2019","unstructured":"Turini S.; Bergandi L.; Gazzano E.; Prato M.; Aldieri E.; Epithelial to mesenchymal transition in human mesothelial cells exposed to asbestos fibers: Role of TGF-\u03b2 as mediator of malignant mesothelioma development or metastasis via EMT event. Int J Mol Sci  2019,20(1),150","journal-title":"Int J Mol Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-019-0180-0","volume":"8","author":"Kim M.K.","year":"2020","unstructured":"Kim M.K.; Kim H.; Jang M.; Oh S.S.; Yong S.J.; Jeong Y.; Jung S.H.; Choi J.W.; LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma. Biomark Res  2020,8(1),1","journal-title":"Biomark Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1038\/oncsis.2013.29","volume":"2","author":"Tamminen J.A.","year":"2013","unstructured":"Tamminen J.A.; Parviainen V.; R\u00f6nty M.; Wohl A.P.; Murray L.; Joenv\u00e4r\u00e4 S.; Varjosalo M.; Lepp\u00e4ranta O.; Ritvos O.; Sengle G.; Renkonen R.; Myll\u00e4rniemi M.; Koli K.; Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis  2013,2(8),e66","journal-title":"Oncogenesis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.3390\/ijms24043496","volume":"24","author":"Stella G.M.","year":"2023","unstructured":"Stella G.M.; Marchi\u00f2 C.; Bari E.; Ferrarotti I.; Bertuccio F.R.; Di Gennaro A.; Abbott D.M.; Putignano P.; Campo I.; Torre M.L.; Corsico A.G.; The genes\u2013stemness\u2013secretome interplay in malignant pleural mesothelioma: molecular dynamics and clinical hints. Int J Mol Sci  2023,24(4),3496","journal-title":"Int J Mol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/bs.acr.2019.03.007","volume":"143","author":"Bacolod M.D.","year":"2019","unstructured":"Bacolod M.D.; Barany F.; Fisher P.B.; Can CpG methylation serve as surrogate markers for immune infiltration in cancer? Adv Cancer Res  2019,143,351-384","journal-title":"Adv Cancer Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"678447","DOI":"10.3389\/fonc.2021.678447","volume":"11","author":"Pinton G.","year":"2021","unstructured":"Pinton G.; Wang Z.; Balzano C.; Missaglia S.; Tavian D.; Boldorini R.; Fennell D.A.; Griffin M.; Moro L.; CDKN2A determines mesothelioma cell fate to EZH2 inhibition. Front Oncol  2021,11,678447","journal-title":"Front Oncol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/2536187","volume":"2017","author":"Cheng Y.Y.","year":"2017","unstructured":"Cheng Y.Y.; Mok E.; Tan S.; Leygo C.; McLaughlin C.; George A.M.; Reid G.; SFRP tumour suppressor genes are potential plasma-based epigenetic biomarkers for malignant pleural mesothelioma. Dis Markers  2017,2017,1-10","journal-title":"Dis Markers"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40248-018-0137-4","volume":"13","author":"Bosio M.","year":"2018","unstructured":"Bosio M.; Salvaterra E.; Datturi F.; Morbini P.; Zorzetto M.; Inghilleri S.; Tomaselli S.; Mangiarotti P.; Meloni F.; Cerveri I.; Stella G.M.; 5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin. Multidiscip Respir Med  2018,13(1),27","journal-title":"Multidiscip Respir Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.lungcan.2018.09.019","volume":"125","author":"Kinoshita Y.","year":"2018","unstructured":"Kinoshita Y.; Hamasaki M.; Yoshimura M.; Matsumoto S.; Sato A.; Tsujimura T.; Ueda H.; Makihata S.; Kato F.; Iwasaki A.; Nabeshima K.; A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. Lung Cancer  2018,125,198-204","journal-title":"Lung Cancer"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3389\/fonc.2020.01742","volume":"10","author":"Rozitis E.","year":"2020","unstructured":"Rozitis E.; Johnson B.; Cheng Y.Y.; Lee K.; The use of immunohistochemistry, fluorescence in situ hybridization, and emerging epigenetic markers in the diagnosis of malignant pleural mesothelioma (MPM): A review. Front Oncol  2020,10,1742","journal-title":"Front Oncol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"350","DOI":"10.21037\/tlcr.2017.06.06","volume":"6","author":"McLoughlin K.C.","year":"2017","unstructured":"McLoughlin K.C.; Kaufman A.S.; Schrump D.S.; Targeting the epigenome in malignant pleural mesothelioma. Transl Lung Cancer Res  2017,6(3),350-365","journal-title":"Transl Lung Cancer Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LaFave L.M.","year":"2015","unstructured":"LaFave L.M.; B\u00e9guelin W.; Koche R.; Teater M.; Spitzer B.; Chramiec A.; Papalexi E.; Keller M.D.; Hricik T.; Konstantinoff K.; Micol J.B.; Durham B.; Knutson S.K.; Campbell J.E.; Blum G.; Shi X.; Doud E.H.; Krivtsov A.V.; Chung Y.R.; Khodos I.; de Stanchina E.; Ouerfelli O.; Adusumilli P.S.; Thomas P.M.; Kelleher N.L.; Luo M.; Keilhack H.; Abdel-Wahab O.; Melnick A.; Armstrong S.A.; Levine R.L.; Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med  2015,21(11),1344-1349","journal-title":"Nat Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.celrep.2014.05.026","volume":"7","author":"Pfister S.X.","year":"2014","unstructured":"Pfister S.X.; Ahrabi S.; Zalmas L.P.; Sarkar S.; Aymard F.; Bachrati C.Z.; Helleday T.; Legube G.; La Thangue N.B.; Porter A.C.G.; Humphrey T.C.; SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep  2014,7(6),2006-2018","journal-title":"Cell Rep"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Sato Y.","year":"2013","unstructured":"Sato Y.; Yoshizato T.; Shiraishi Y.; Maekawa S.; Okuno Y.; Kamura T.; Shimamura T.; Sato-Otsubo A.; Nagae G.; Suzuki H.; Nagata Y.; Yoshida K.; Kon A.; Suzuki Y.; Chiba K.; Tanaka H.; Niida A.; Fujimoto A.; Tsunoda T.; Morikawa T.; Maeda D.; Kume H.; Sugano S.; Fukayama M.; Aburatani H.; Sanada M.; Miyano S.; Homma Y.; Ogawa S.; Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet  2013,45(8),860-867","journal-title":"Nat Genet"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ng.2894","volume":"46","author":"Zhu X.","year":"2014","unstructured":"Zhu X.; He F.; Zeng H.; Ling S.; Chen A.; Wang Y.; Yan X.; Wei W.; Pang Y.; Cheng H.; Hua C.; Zhang Y.; Yang X.; Lu X.; Cao L.; Hao L.; Dong L.; Zou W.; Wu J.; Li X.; Zheng S.; Yan J.; Zhou J.; Zhang L.; Mi S.; Wang X.; Zhang L.; Zou Y.; Chen Y.; Geng Z.; Wang J.; Zhou J.; Liu X.; Wang J.; Yuan W.; Huang G.; Cheng T.; Wang Q.; Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet  2014,46(3),287-293","journal-title":"Nat Genet"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","volume":"16","author":"Cooper J.","year":"2017","unstructured":"Cooper J.; Xu Q.; Zhou L.; Pavlovic M.; Ojeda V.; Moulick K.; de Stanchina E.; Poirier J.T.; Zauderer M.; Rudin C.M.; Karajannis M.A.; Hanemann C.O.; Giancotti F.G.; Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss\u2013driven tumorigenesis. Mol Cancer Ther  2017,16(8),1693-1704","journal-title":"Mol Cancer Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1158\/1541-7786.MCR-19-0564","volume":"18","author":"Rossi T.","year":"2020","unstructured":"Rossi T.; Pistoni M.; Sancisi V.; Gobbi G.; Torricelli F.; Donati B.; Ribisi S.; Gugnoni M.; Ciarrocchi A.; RAIN is a novel enhancer-associated lncRNA that controls RUNX2 expression and pomotes breast and thyroid cancer. Mol Cancer Res  2020,18(1),140-152","journal-title":"Mol Cancer Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/ijms17101712","volume":"17","author":"Catalanotto C.","year":"2016","unstructured":"Catalanotto C.; Cogoni C.; Zardo G.; MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci  2016,17(10),1712","journal-title":"Int J Mol Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.2147\/CMAR.S205723","volume":"11","author":"Ospina D.","year":"2019","unstructured":"Ospina D.; Villegas V.E.; Rodr\u00edguez-Leguizam\u00f3n G.; Rond\u00f3n-Lagos M.; Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos. Cancer Manag Res  2019,11,4997-5012","journal-title":"Cancer Manag Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/1055-9965.EPI-18-0453","volume":"28","author":"Santarelli L.","year":"2019","unstructured":"Santarelli L.; Gaetani S.; Monaco F.; Bracci M.; Valentino M.; Amati M.; Rubini C.; Sabbatini A.; Pasquini E.; Zanotta N.; Comar M.; Neuzil J.; Tomasetti M.; Bovenzi M.; Four-miRNA signature to identify asbestos-related lung malignancies. Cancer Epidemiol Biomarkers Prev  2019,28(1),119-126","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","volume":"24","author":"Reid G.","year":"2013","unstructured":"Reid G.; Pel M.E.; Kirschner M.B.; Cheng Y.Y.; Mugridge N.; Weiss J.; Williams M.; Wright C.; Edelman J.J.B.; Vallely M.P.; McCaughan B.C.; Klebe S.; Brahmbhatt H.; MacDiarmid J.A.; van Zandwijk N.; Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol  2013,24(12),3128-3135","journal-title":"Ann Oncol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/9645940","volume":"2017","author":"Mozzoni P.","year":"2017","unstructured":"Mozzoni P.; Ampollini L.; Goldoni M.; Alinovi R.; Tiseo M.; Gnetti L.; Carbognani P.; Rusca M.; Mutti A.; Percesepe A.; Corradi M.; MicroRNA expression in malignant pleural mesothelioma and asbestosis: A pilot study. Dis Markers  2017,2017,1-10","journal-title":"Dis Markers"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry S.","year":"2017","unstructured":"Hendry S.; Salgado R.; Gevaert T.; Russell P.A.; John T.; Thapa B.; Christie M.; van de Vijver K.; Estrada M.V.; Gonzalez-Ericsson P.I.; Sanders M.; Solomon B.; Solinas C.; Van den Eynden G.G.G.M.; Allory Y.; Preusser M.; Hainfellner J.; Pruneri G.; Vingiani A.; Demaria S.; Symmans F.; Nuciforo P.; Comerma L.; Thompson E.A.; Lakhani S.; Kim S.R.; Schnitt S.; Colpaert C.; Sotiriou C.; Scherer S.J.; Ignatiadis M.; Badve S.; Pierce R.H.; Viale G.; Sirtaine N.; Penault-Llorca F.; Sugie T.; Fineberg S.; Paik S.; Srinivasan A.; Richardson A.; Wang Y.; Chmielik E.; Brock J.; Johnson D.B.; Balko J.; Wienert S.; Bossuyt V.; Michiels S.; Ternes N.; Burchardi N.; Luen S.J.; Savas P.; Klauschen F.; Watson P.H.; Nelson B.H.; Criscitiello C.; O\u2019Toole S.; Larsimont D.; de Wind R.; Curigliano G.; Andr\u00e9 F.; Lacroix-Triki M.; van de Vijver M.; Rojo F.; Floris G.; Bedri S.; Sparano J.; Rimm D.; Nielsen T.; Kos Z.; Hewitt S.; Singh B.; Farshid G.; Loibl S.; Allison K.H.; Tung N.; Adams S.; Willard-Gallo K.; Horlings H.M.; Gandhi L.; Moreira A.; Hirsch F.; Dieci M.V.; Urbanowicz M.; Brcic I.; Korski K.; Gaire F.; Koeppen H.; Lo A.; Giltnane J.; Rebelatto M.C.; Steele K.E.; Zha J.; Emancipator K.; Juco J.W.; Denkert C.; Reis-Filho J.; Loi S.; Fox S.B.; Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non\u2013Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol  2017,24(6),311-335","journal-title":"Adv Anat Pathol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"16456","DOI":"10.1038\/s41598-017-16551-7","volume":"7","author":"Klikovits T.","year":"2017","unstructured":"Klikovits T.; Stockhammer P.; Laszlo V.; Dong Y.; Hoda M.A.; Ghanim B.; Opitz I.; Frauenfelder T.; Nguyen-Kim T.D.L.; Weder W.; Berger W.; Grusch M.; Aigner C.; Klepetko W.; Dome B.; Renyi-Vamos F.; Oehler R.; Hegedus B.; Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Sci Rep  2017,7(1),16456","journal-title":"Sci Rep"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/bjc.2013.815","volume":"110","author":"Ghanim B.","year":"2014","unstructured":"Ghanim B.; Hoda M.A.; Klikovits T.; Winter M-P.; Alimohammadi A.; Grusch M.; Dome B.; Arns M.; Schenk P.; Jakopovic M.; Samarzija M.; Brcic L.; Filipits M.; Laszlo V.; Klepetko W.; Berger W.; Hegedus B.; Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br J Cancer  2014,110(4),984-990","journal-title":"Br J Cancer"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/cancers13040658","volume":"13","author":"Vogl M.","year":"2021","unstructured":"Vogl M.; Rosenmayr A.; Bohanes T.; Scheed A.; Brndiar M.; Stubenberger E.; Ghanim B.; Biomarkers for malignant pleural mesothelioma-A novel view on inflammation. Cancers  2021,13(4),658","journal-title":"Cancers"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/1568026615666150825141152","volume":"16","author":"Hamaidia M.","year":"2015","unstructured":"Hamaidia M.; Staumont B.; Duysinx B.; Louis R.; Willems L.; Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators. Curr Top Med Chem  2015,16(7),777-787","journal-title":"Curr Top Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3892\/ijo.2012.1715","volume":"42","author":"Cregan I.L.","year":"2013","unstructured":"Cregan I.L.; Dharmarajan A.M.; Fox S.A.; Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: Role of inhibitor of apoptosis proteins (IAPs) and caspases. Int J Oncol  2013,42(2),444-452","journal-title":"Int J Oncol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1038\/cddis.2013.258","volume":"4","author":"Crawford N.","year":"2013","unstructured":"Crawford N.; Stasik I.; Holohan C.; Majkut J.; McGrath M.; Johnston P.G.; Chessari G.; Ward G.A.; Waugh D.J.; Fennell D.A.; Longley D.B.; SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma. Cell Death Dis  2013,4(7),e733","journal-title":"Cell Death Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.ijrobp.2019.11.029","volume":"106","author":"Jackson M.R.","year":"2020","unstructured":"Jackson M.R.; Ashton M.; Koessinger A.L.; Dick C.; Verheij M.; Chalmers A.J.; Mesothelioma cells depend on the antiapoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. Int J Radiat Oncol Biol Phys  2020,106(4),867-877","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/cc.27546","volume":"13","author":"Di Marzo D.","year":"2014","unstructured":"Di Marzo D.; Forte I.M.; Indovina P.; Di Gennaro E.; Rizzo V.; Giorgi F.; Mattioli E.; Iannuzzi C.A.; Budillon A.; Giordano A.; Pentimalli F.; Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle  2014,13(4),652-665","journal-title":"Cell Cycle"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s13046-021-02118-y","volume":"40","author":"Cioce M.","year":"2021","unstructured":"Cioce M.; Canino C.; Pass H.; Blandino G.; Strano S.; Fazio V.M.; Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. J Exp Clin Cancer Res  2021,40(1),344","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e1757","DOI":"10.1038\/cddis.2015.124","volume":"6","author":"Echeverry N.","year":"2015","unstructured":"Echeverry N.; Ziltener G.; Barbone D.; Weder W.; Stahel R.A.; Broaddus V.C.; Felley-Bosco E.; Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors. Cell Death Dis  2015,6(5),e1757","journal-title":"Cell Death Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.3390\/ijms23063278","volume":"23","author":"Mathilakathu A.","year":"2022","unstructured":"Mathilakathu A.; Wessolly M.; Mairinger E.; Uebner H.; Kreidt D.; Brcic L.; Steinborn J.; Greimelmaier K.; Wohlschlaeger J.; Schmid K.W.; Mairinger F.D.; Borchert S.; Cancer-associated fibroblasts regulate kinase activity in mesothelioma cell lines via paracrine signaling and thereby dictate cell faith and behavior. Int J Mol Sci  2022,23(6),3278","journal-title":"Int J Mol Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41418-020-00709-4","volume":"28","author":"Masclef L.","year":"2021","unstructured":"Masclef L.; Ahmed O.; Estavoyer B.; Larriv\u00e9e B.; Labrecque N.; Nijnik A.; Affar E.B.; Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ  2021,28(2),606-625","journal-title":"Cell Death Differ"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"101223","DOI":"10.1016\/j.jbc.2021.101223","volume":"297","author":"Ishii Y.","year":"2021","unstructured":"Ishii Y.; Kolluri K.K.; Pennycuick A.; Zhang X.; Nigro E.; Alrifai D.; Borg E.; Falzon M.; Shah K.; Kumar N.; Janes S.M.; BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. J Biol Chem  2021,297(5),101223","journal-title":"J Biol Chem"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"e30224","DOI":"10.7554\/eLife.30224","volume":"7","author":"Kolluri K.K.","year":"2018","unstructured":"Kolluri K.K.; Alifrangis C.; Kumar N.; Ishii Y.; Price S.; Michaut M.; Williams S.; Barthorpe S.; Lightfoot H.; Busacca S.; Sharkey A.; Yuan Z.; Sage E.K.; Vallath S.; Le Quesne J.; Tice D.A.; Alrifai D.; von Karstedt S.; Montinaro A.; Guppy N.; Waller D.A.; Nakas A.; Good R.; Holmes A.; Walczak H.; Fennell D.A.; Garnett M.; Iorio F.; Wessels L.; McDermott U.; Janes S.M.; Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife  2018,7,e30224","journal-title":"eLife"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","volume":"27","author":"Oehl K.","year":"2021","unstructured":"Oehl K.; Vrugt B.; Wagner U.; Kirschner M.B.; Meerang M.; Weder W.; Felley-Bosco E.; Wollscheid B.; Bankov K.; Demes M.C.; Opitz I.; Wild P.J.; Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma. Clin Cancer Res  2021,27(8),2277-2291","journal-title":"Clin Cancer Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","volume":"23","author":"Kindler H.L.","year":"2022","unstructured":"Kindler H.L.; Novello S.; Bearz A.; Ceresoli G.L.; Aerts J.G.J.V.; Spicer J.; Taylor P.; Nackaerts K.; Greystoke A.; Jennens R.; Calabr\u00f2 L.; Burgers J.A.; Santoro A.; Cedr\u00e9s S.; Serwatowski P.; Ponce S.; Van Meerbeeck J.P.; Nowak A.K.; Blumenschein G.; Siegel J.M.; Kasten L.; K\u00f6chert K.; Walter A.O.; Childs B.H.; Elbi C.; Hassan R.; Fennell D.A.; Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin- positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol  2022,23(4),540-552","journal-title":"Lancet Oncol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejmech.2017.07.063","volume":"142","author":"Facchetti G.","year":"2017","unstructured":"Facchetti G.; Petrella F.; Spaggiari L.; Rimoldi I.; Malignant Pleural Mesothelioma: State of the art and advanced cell therapy. Eur J Med Chem  2017,142,266-270","journal-title":"Eur J Med Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"Rottenberg S.","year":"2021","unstructured":"Rottenberg S.; Disler C.; Perego P.; The rediscovery of platinum-based cancer therapy. Nat Rev Cancer  2021,21(1),37-50","journal-title":"Nat Rev Cancer"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.3390\/molecules27196229","volume":"27","author":"Kovalev I.S.","year":"2022","unstructured":"Kovalev I.S.; Zyryanov G.V.; Santra S.; Majee A.; Varaksin M.V.; Charushin V.N.; Folic acid antimetabolites (antifolates): A brief review on synthetic strategies and application opportunities. Molecules  2022,27(19),6229","journal-title":"Molecules"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13205-023-03636-6","volume":"13","author":"Banyal A.","year":"2023","unstructured":"Banyal A.; Tiwari S.; Sharma A.; Chanana I.; Patel S.K.S.; Kulshrestha S.; Kumar P.; Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. 3 Biotech  2023,13(6),211","journal-title":"3 Biotech"},{"key":"ref=106","author":"Sinawe H.","year":"2023","unstructured":"Sinawe H.; Casadesus D.; Mitomycin. StatPearls  2023","journal-title":"StatPearls"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"Zalcman G.","year":"2016","unstructured":"Zalcman G.; Mazieres J.; Margery J.; Greillier L.; Audigier-Valette C.; Moro-Sibilot D.; Molinier O.; Corre R.; Monnet I.; Gounant V.; Rivi\u00e8re F.; Janicot H.; Gervais R.; Locher C.; Milleron B.; Tran Q.; Lebitasy M.P.; Morin F.; Creveuil C.; Parienti J.J.; Scherpereel A.; Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet  2016,387(10026),1405-1414","journal-title":"Lancet"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"Ma S.","year":"2019","unstructured":"Ma S.; Meng Z.; Chen R.; Guan K.L.; The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem  2019,88(1),577-604","journal-title":"Annu Rev Biochem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41416-019-0379-8","volume":"120","author":"Maille E.","year":"2019","unstructured":"Maille E.; Brosseau S.; Hanoux V.; Creveuil C.; Danel C.; Bergot E.; Scherpereel A.; Mazi\u00e8res J.; Margery J.; Greillier L.; Audigier-Valette C.; Moro-Sibilot D.; Molinier O.; Corre R.; Monnet I.; Gounant V.; Langlais A.; Morin F.; Levallet G.; Zalcman G.; MST1\/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. Br J Cancer  2019,120(4),387-397","journal-title":"Br J Cancer"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/CS20201474","volume":"136","author":"Cunningham R.","year":"2022","unstructured":"Cunningham R.; Hansen C.G.; The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond)  2022,136(3),197-222","journal-title":"Clin Sci (Lond)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11523-022-00900-2","volume":"17","author":"Dubois F.","year":"2022","unstructured":"Dubois F.; Bazille C.; Levallet J.; Maille E.; Brosseau S.; Madelaine J.; Bergot E.; Zalcman G.; Levallet G.; Molecular alterations in malignant pleural mesothelioma: A hope for effective treatment by targeting YAP. Target Oncol  2022,17(4),407-431","journal-title":"Target Oncol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","volume":"16","author":"Krug L.M.","year":"2015","unstructured":"Krug L.M.; Kindler H.L.; Calvert H.; Manegold C.; Tsao A.S.; Fennell D.; \u00d6hman R.; Plummer R.; Eberhardt W.E.E.; Fukuoka K.; Gaafar R.M.; Lafitte J.J.; Hillerdal G.; Chu Q.; Buikhuisen W.A.; Lubiniecki G.M.; Sun X.; Smith M.; Baas P.; Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol  2015,16(4),447-456","journal-title":"Lancet Oncol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fonc.2020.00343","volume":"12","author":"Cantini L.","year":"2020","unstructured":"Cantini L.; Hassan R.; Sterman D.H.; Aerts J.G.J.V.; Emerging treatments for malignant pleural mesothelioma: where are we heading? Front Oncol  2020,12(10),343","journal-title":"Front Oncol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1471-2407-14-304","volume":"14","author":"Cortes-Dericks L.","year":"2014","unstructured":"Cortes-Dericks L.; Froment L.; Boesch R.; Schmid R.A.; Karoubi G.; Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity. BMC Cancer  2014,14(1),304","journal-title":"BMC Cancer"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.3390\/molecules26164740","volume":"26","author":"Gabano E.","year":"2021","unstructured":"Gabano E.; Pinton G.; Balzano C.; Boumya S.; Osella D.; Moro L.; Ravera M.; Unsymmetric cisplatin-based pt(iv) conjugates containing a parp-1 inhibitor pharmacophore tested on malignant pleural mesothelioma cell lines. Molecules  2021,26(16),4740","journal-title":"Molecules"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3892\/or.2015.3830","volume":"33","author":"Hwang K.E.","year":"2015","unstructured":"Hwang K.E.; Kim Y.S.; Hwang Y.R.; Kwon S.J.; Park D.S.; Cha B.K.; Kim B.R.; Yoon K.H.; Jeong E.T.; Kim H.R.; Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1. Oncol Rep  2015,33(5),2411-2419","journal-title":"Oncol Rep"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/cancers11101446","volume":"11","author":"Papazoglou E.D.","year":"2019","unstructured":"Papazoglou E.D.; Jagirdar R.M.; Kouliou O.A.; Pitaraki E.; Hatzoglou C.; Gourgoulianis K.I.; Zarogiannis S.G.; In Vitro characterization of cisplatin and pemetrexed effects in malignant pleural mesothelioma 3d culture phenotypes. Cancers  2019,11(10),1446","journal-title":"Cancers"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1200\/JCO.22.02720","volume":"41","author":"Stinchcombe T.E.","year":"2023","unstructured":"Stinchcombe T.E.; Flashback Foreword: Pemetrexed and cisplatin in mesothelioma. J Clin Oncol  2023,41(12),2123-2124","journal-title":"J Clin Oncol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"76577","DOI":"10.18632\/oncotarget.10428","volume":"7","author":"Monica V.","year":"2016","unstructured":"Monica V.; Iacono M.L.; Bracco E.; Busso S.; Blasio L.D.; Primo L.; Peracino B.; Papotti M.; Scagliotti G.; Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. Oncotarget  2016,7(47),76577-76589","journal-title":"Oncotarget"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"11248","DOI":"10.3390\/ijms231911248","volume":"23","author":"Gesmundo I.","year":"2022","unstructured":"Gesmundo I.; Pedrolli F.; Vitale N.; Bertoldo A.; Orlando G.; Banfi D.; Granato G.; Kasarla R.; Balzola F.; Deaglio S.; Cai R.; Sha W.; Papotti M.; Ghigo E.; Schally A.V.; Granata R.; Antagonist of growth hormone-releasing hormone potentiates the antitumor effect of pemetrexed and cisplatin in pleural mesothelioma. Int J Mol Sci  2022,23(19),11248","journal-title":"Int J Mol Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21037\/tlcr-21-765","volume":"11","author":"Sun R.","year":"2022","unstructured":"Sun R.; Tanino R.; Tong X.; Haque E.F.; Amano Y.; Isobe T.; Tsubata Y.; Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways. Transl Lung Cancer Res  2022,11(4),543-559","journal-title":"Transl Lung Cancer Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13046-022-02284-7","volume":"41","author":"Salaroglio I.C.","year":"2022","unstructured":"Salaroglio I.C.; Belisario D.C.; Bironzo P.; Ananthanarayanan P.; Ricci L.; Digiovanni S.; Fontana S.; Napoli F.; Sandri A.; Facolmat\u00e0 C.; Libener R.; Comunanza V.; Grosso F.; Gazzano E.; Leo F.; Taulli R.; Bussolino F.; Righi L.; Papotti M.G.; Novello S.; Scagliotti G.V.; Riganti C.; Kopecka J.; SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. J Exp Clin Cancer Res  2022,41(1),75","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"9014","DOI":"10.3390\/ijms22169014","volume":"22","author":"Lisini D.","year":"2021","unstructured":"Lisini D.; Lettieri S.; Nava S.; Accordino G.; Frigerio S.; Bortolotto C.; Lancia A.; Filippi A.R.; Agustoni F.; Pandolfi L.; Piloni D.; Comoli P.; Corsico A.G.; Stella G.M.; Local therapies and modulation of tumor surrounding stroma in malignant pleural mesothelioma: A translational approach. Int J Mol Sci  2021,22(16),9014","journal-title":"Int J Mol Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2015.10.019","volume":"228","author":"Ando H.","year":"2015","unstructured":"Ando H.; Kobayashi S.; Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed. Control Release  2015,228(Pt A),29-36","journal-title":"Control Release"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.biopha.2017.01.118","volume":"87","author":"Petrella F.","year":"2017","unstructured":"Petrella F.; Cocc\u00e8 V.; Masia C.; Milani M.; Sal\u00e8 E.O.; Alessandri G.; Parati E.; Sisto F.; Pentimalli F.; Brini A.T.; Pessina A.; Spaggiari L.; Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells. Biomed Pharmacother  2017,87,755-758","journal-title":"Biomed Pharmacother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/medicines4040087","volume":"4","author":"Petrella F.","year":"2017","unstructured":"Petrella F.; Rimoldi I.; Rizzo S.; Spaggiari L.; Mesenchymal stromal cells for antineoplastic drug loading and delivery. Medicines  2017,4(4),87","journal-title":"Medicines"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.3390\/ijms21155432","volume":"21","author":"Burgio S.","year":"2020","unstructured":"Burgio S.; Noori L.; Marino Gammazza A.; Campanella C.; Logozzi M.; Fais S.; Bucchieri F.; Cappello F.; Caruso Bavisotto C.; Extracellular vesicles-based drug delivery systems: A new challenge and the exemplum of malignant pleural mesothelioma. Int J Mol Sci  2020,21(15),5432","journal-title":"Int J Mol Sci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12032-014-0458-x","volume":"32","author":"de Lima V.A.B.","year":"2015","unstructured":"de Lima V.A.B.; S\u00f8rensen J.B.; Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma. Med Oncol  2015,32(2),11","journal-title":"Med Oncol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejps.2015.09.015","volume":"81","author":"Eldin N.E.","year":"2016","unstructured":"Eldin N.E.; Abu Lila A.S.; Kawazoe K.; Elnahas H.M.; Mahdy M.A.; Ishida T.; Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model. Eur J Pharm Sci  2016,81,60-66","journal-title":"Eur J Pharm Sci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.2147\/IJN.S202568","volume":"14","author":"Marazioti A.","year":"2019","unstructured":"Marazioti A.; Papadia K.; Giannou A.; Stathopoulos G.T.; Antimisiaris S.; Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection. Int J Nanomedicine  2019,14,3773-3784","journal-title":"Int J Nanomedicine"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/IJN.S186344","volume":"14","author":"Cova E.","year":"2019","unstructured":"Cova E.; Pandolfi L.; Colombo M.; Frangipane V.; Inghilleri S.; Morosini M.; Mrakic-Sposta S.; Moretti S.; Monti M.; Pignochino Y.; Benvenuti S.; Prosperi D.; Stella G.; Morbini P.; Meloni F.; Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: An in vitro study. Int J Nanomedicine  2019,14,773-785","journal-title":"Int J Nanomedicine"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/rcr2.145","volume":"4","author":"Kanai O.","year":"2016","unstructured":"Kanai O.; Fujita K.; Nakatani K.; Mio T.; Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma. Respirol Case Rep  2016,4(1),28-31","journal-title":"Respirol Case Rep"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1021\/acs.molpharmaceut.1c00797","volume":"19","author":"Amano Y.","year":"2022","unstructured":"Amano Y.; Sakura K.L.; Ohta S.; Ito T.; Cisplatin\u2013chelated iminodiacetic acid\u2013conjugated hyaluronic acid nanogels for the treatment of malignant pleural mesothelioma in mice. Mol Pharm  2022,19(3),853-861","journal-title":"Mol Pharm"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jtcvs.2019.07.073","volume":"159","author":"Opitz I.","year":"2020","unstructured":"Opitz I.; Lauk O.; Meerang M.; Jetter A.; Aeschlimann B.; Seifert B.; G\u00fcnther D.; Stahel R.A.; Weder W.; Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial. J Thorac Cardiovasc Surg  2020,159(1),330-340.e4","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/pharmaceutics12050411","volume":"12","author":"Lisini D.","year":"2020","unstructured":"Lisini D.; Nava S.; Frigerio S.; Pogliani S.; Maronati G.; Marcianti A.; Cocc\u00e8 V.; Bondiolotti G.; Cavicchini L.; Paino F.; Petrella F.; Alessandri G.; Parati E.A.; Pessina A.; Automated large-scale production of paclitaxel loaded mesenchymal stromal cells for cell therapy applications. Pharmaceutics  2020,12(5),411","journal-title":"Pharmaceutics"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.3390\/ijms23052745","volume":"23","author":"Szewc M.","year":"2022","unstructured":"Szewc M.; Radzikowska-B\u0171chner E.; Wdowiak P.; Kozak J.; Kuszta P.; Niezabitowska E.; Matysiak J.; Kubi\u0144ski K.; Mas\u0142yk M.; MSCs as tumor-specific vectors for the delivery of anticancer agents-a potential therapeutic strategy in cancer diseases: perspectives for quinazoline derivatives. Int J Mol Sci  2022,23(5),2745","journal-title":"Int J Mol Sci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-015-0200-3","volume":"34","author":"Pessina A.","year":"2015","unstructured":"Pessina A.; Leonetti C.; Artuso S.; Benetti A.; Dessy E.; Pascucci L.; Passeri D.; Orlandi A.; Berenzi A.; Bonomi A.; Cocc\u00e8 V.; Ceserani V.; Ferri A.; Dossena M.; Mazzuca P.; Ciusani E.; Ceccarelli P.; Caruso A.; Portolani N.; Sisto F.; Parati E.; Alessandri G.; Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. J Exp Clin Cancer Res  2015,34(1),82","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.3390\/ijms24065864","volume":"24","author":"Cordani N.","year":"2023","unstructured":"Cordani N.; Lisini D.; Cocc\u00e8 V.; Paglia G.; Meanti R.; Cerrito M.G.; Tettamanti P.; Bonaffini L.; Paino F.; Alessandri G.; Marcianti A.; Giann\u00ec A.; Villa C.; Mauri M.; Mologni L.; Torsello A.; Pessina A.; Cazzaniga M.E.; Conditioned medium of mesenchymal stromal cells loaded with paclitaxel is effective in preclinical models of triple-negative dreast cancer (TNBC). Int J Mol Sci  2023,24(6),5864","journal-title":"Int J Mol Sci"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"115678","DOI":"10.1016\/j.bcp.2023.115678","volume":"214","author":"Cocc\u00e8 V.","year":"2023","unstructured":"Cocc\u00e8 V.; Bonelli M.; La Monica S.; Alfieri R.; Doneda L.; Martegani E.; Alessandri G.; Lagrasta C.A.; Giann\u00ec A.; Sordi V.; Petrella F.; Roncoroni L.; Paino F.; Pessina A.; Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma. Biochem Pharmacol  2023,214,115678","journal-title":"Biochem Pharmacol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","volume":"30","author":"Colombo M.","year":"2014","unstructured":"Colombo M.; Raposo G.; Th\u00e9ry C.; Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol  2014,30(1),255-289","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jconrel.2019.07.022","volume":"309","author":"Bari E.","year":"2019","unstructured":"Bari E.; Ferrarotti I.; Torre M.L.; Corsico A.G.; Perteghella S.; Mesenchymal stem\/stromal cell secretome for lung regeneration: The long way through \u201cpharmaceuticalization\u201d for the best formulation. J Control Release  2019,309,11-24","journal-title":"J Control Release"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.semcancer.2020.08.007","volume":"80","author":"Pirisinu M.","year":"2022","unstructured":"Pirisinu M.; Pham T.C.; Zhang D.X.; Hong T.N.; Nguyen L.T.; Le M.T.N.; Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation. Semin Cancer Biol  2022,80,340-355","journal-title":"Semin Cancer Biol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/cancers12102948","volume":"12","author":"Pagano M.","year":"2020","unstructured":"Pagano M.; Ceresoli L.G.; Zucali P.A.; Pasello G.; Garassino M.; Grosso F.; Tiseo M.; Soto Parra H.; Zanelli F.; Cappuzzo F.; Grossi F.; De Marinis F.; Pedrazzoli P.; Gnoni R.; Bonelli C.; Torricelli F.; Ciarrocchi A.; Normanno N.; Pinto C.; Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study. Cancers  2020,12(10),2948","journal-title":"Cancers"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","volume":"11","author":"Kim J.E.","year":"2018","unstructured":"Kim J.E.; Kim D.; Hong Y.S.; Kim K.; Yoon Y.K.; Lee D.H.; Kim S.W.; Chun S.M.; Jang S.J.; Kim T.W.; Mutational profiling of malignant mesothelioma revealed potential therapeutic targets in EGFR and NRAS. Transl Oncol  2018,11(2),268-274","journal-title":"Transl Oncol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.3390\/ijms24119165","volume":"24","author":"Borea F.","year":"2023","unstructured":"Borea F.; Franczak M.A.; Garcia M.; Perrino M.; Cordua N.; Smolenski R.T.; Peters G.J.; Dziadziuszko R.; Santoro A.; Zucali P.A.; Giovannetti E.; Target therapy in malignant pleural mesothelioma: hope or mirage? Int J Mol Sci  2023,24(11),9165","journal-title":"Int J Mol Sci"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.3390\/cancers14246063","volume":"14","author":"Gemelli M.","year":"2022","unstructured":"Gemelli M.; Cortinovis D.L.; Baggi A.; di Mauro P.; Calza S.; Berruti A.; Grisanti S.; Rota M.; Immune checkpoint inhibitors in malignant pleural mesothelioma: a systematic review and meta-analysis. Cancers  2022,14(24),6063","journal-title":"Cancers"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"7467","DOI":"10.21037\/jtd-19-2267","volume":"12","author":"Brown L.B.","year":"2020","unstructured":"Brown L.B.; Corl F.; Blackmon S.H.; Surgical staging and resection of malignant pleural mesothelioma. J Thorac Dis  2020,12(12),7467-7480","journal-title":"J Thorac Dis"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"212","DOI":"10.21037\/tlcr.2017.04.01","volume":"6","author":"Alley E.W.","year":"2007","unstructured":"Alley E.W.; Katz S.I.; Cengel K.A.; Simone C.B.; Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res  2007,6(2),212-219","journal-title":"Transl Lung Cancer Res"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/ph16071042","volume":"16","author":"Stella G.M.","year":"2023","unstructured":"Stella G.M.; Lettieri S.; Piloni D.; Ferrarotti I.; Perrotta F.; Corsico A.G.; Bortolotto C.; Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer. Pharmaceuticals  2023,16(7),1042","journal-title":"Pharmaceuticals"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"Mansfield A.S.","year":"2014","unstructured":"Mansfield A.S.; Roden A.C.; Peikert T.; Sheinin Y.M.; Harrington S.M.; Krco C.J.; Dong H.; Kwon E.D.; B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol  2014,9(7),1036-1040","journal-title":"J Thorac Oncol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fonc.2017.00179","volume":"7","author":"Pease D.F.","year":"2017","unstructured":"Pease D.F.; Kratzke R.A.; Oncolytic Viral Therapy for Mesothelioma. Front Oncol  2017,7,179","journal-title":"Front Oncol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"192","DOI":"10.33696\/immunology.2.042","volume":"2","author":"Klampatsa A.","year":"2020","unstructured":"Klampatsa A.; Albelda S.M.; Current advances in CAR T aell therapy for malignant mesothelioma. J Cell Immunol  2020,2(4),192-200","journal-title":"J Cell Immunol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673268206240405084558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/228970\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673268206240405084558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:05:13Z","timestamp":1745409913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/228970\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":152,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673268206240405084558","relation":{},"ISSN":["0929-8673"],"issn-type":[{"type":"print","value":"0929-8673"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}